Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Vitrolife AB ( (SE:VITR) ) is now available.
Vitrolife reported first-quarter 2026 sales of SEK 807 million, representing 5% growth in local currencies but a 4% decline in Swedish kronor, with strong demand in the Americas and APAC and solid gains in consumables and technologies. Profitability remained robust as gross margin improved to 59.9% and the EBITDA margin edged up to 31.1%, net income was stable at SEK 101 million, cash flow strengthened markedly, and the nomination committee proposed two new board members, underscoring ongoing efforts to support the company’s growth and governance.
The regional sales mix and product group performance indicate a resilient core business despite currency headwinds, with steady earnings per share suggesting stable returns for shareholders. Improved operating cash flow and a stronger margin profile enhance Vitrolife’s financial flexibility, while the planned board changes may influence strategic direction as the company seeks to consolidate its position in the global fertility and medical technology market.
More about Vitrolife AB
Vitrolife AB is a medical technology company focused on products and technologies used in fertility treatments and assisted reproduction. Its portfolio spans consumables, laboratory technologies and genetic testing solutions, with a global sales footprint across EMEA, the Americas and the Asia-Pacific region.
Average Trading Volume: 319,453
Technical Sentiment Signal: Sell
Current Market Cap: SEK14.91B
For a thorough assessment of VITR stock, go to TipRanks’ Stock Analysis page.